Logo image of ME

23ANDME HOLDING CO -CLASS A (ME) Stock Price, Quote, News and Overview

NASDAQ:ME - Nasdaq - US90138Q3065 - Common Stock - Currency: USD

2.42  -0.32 (-11.68%)

After market: 2.5 +0.08 (+3.31%)

ME Quote, Performance and Key Statistics

23ANDME HOLDING CO -CLASS A

NASDAQ:ME (2/21/2025, 8:00:01 PM)

After market: 2.5 +0.08 (+3.31%)

2.42

-0.32 (-11.68%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Services
Statistics
52 Week High13.74
52 Week Low2.42
Market Cap64.93M
Shares26.83M
Float17.61M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-06 2020-10-06


ME short term performance overview.The bars show the price performance of ME in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ME long term performance overview.The bars show the price performance of ME in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ME is 2.42 USD. In the past month the price decreased by -31.25%. In the past year, price decreased by -78.59%.

23ANDME HOLDING CO -CLASS A / ME Daily stock chart

ME Competitors/Peers

The largest stocks on the US markets in the "Health Care Services" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
CI THE CIGNA GROUP 10.97 82.08B
CVS CVS HEALTH CORP 11.71 79.88B
LH LABCORP HOLDINGS INC 17.15 20.84B
DGX QUEST DIAGNOSTICS INC 19.1 19.12B
FMS FRESENIUS MEDICAL CARE-ADR 13.74 13.55B
BTSGU BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 148.77 12.18B
DVA DAVITA INC 14.99 11.68B
HIMS HIMS & HERS HEALTH INC 112 10.77B
CHE CHEMED CORP 23.84 8.18B
CRVL CORVEL CORP 25.97 5.57B
OPCH OPTION CARE HEALTH INC 26.89 5.45B
GH GUARDANT HEALTH INC N/A 5.30B

About ME

Company Profile

ME logo image 23andMe Holding Co. is a US-based company operating in Health Care Providers & Services industry. The company is headquartered in South San Francisco, California and currently employs 560 full-time employees. The company went IPO on 2020-10-06. 23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The firm operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Company Info

23ANDME HOLDING CO -CLASS A

349 Oyster Point Boulevard

South San Francisco CALIFORNIA US

CEO: Josh Bayliss

Employees: 571

Company Website: https://investors.23andme.com/

Investor Relations: https://investors.23andme.com/

Phone: 16509386300

23ANDME HOLDING CO -CLASS A / ME FAQ

What is the stock price of 23ANDME HOLDING CO -CLASS A today?

The current stock price of ME is 2.42 USD. The price decreased by -11.68% in the last trading session.


What is the ticker symbol for 23ANDME HOLDING CO -CLASS A stock?

The exchange symbol of 23ANDME HOLDING CO -CLASS A is ME and it is listed on the Nasdaq exchange.


On which exchange is ME stock listed?

ME stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for 23ANDME HOLDING CO -CLASS A stock?

10 analysts have analysed ME and the average price target is 2.12 USD. This implies a price decrease of -12.33% is expected in the next year compared to the current price of 2.42. Check the 23ANDME HOLDING CO -CLASS A stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is 23ANDME HOLDING CO -CLASS A worth?

23ANDME HOLDING CO -CLASS A (ME) has a market capitalization of 64.93M USD. This makes ME a Micro Cap stock.


How many employees does 23ANDME HOLDING CO -CLASS A have?

23ANDME HOLDING CO -CLASS A (ME) currently has 571 employees.


What are the support and resistance levels for 23ANDME HOLDING CO -CLASS A (ME) stock?

23ANDME HOLDING CO -CLASS A (ME) has a resistance level at 3.02. Check the full technical report for a detailed analysis of ME support and resistance levels.


Is 23ANDME HOLDING CO -CLASS A (ME) expected to grow?

The Revenue of 23ANDME HOLDING CO -CLASS A (ME) is expected to grow by 22.44% in the next year. Check the estimates tab for more information on the ME EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy 23ANDME HOLDING CO -CLASS A (ME) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does 23ANDME HOLDING CO -CLASS A (ME) stock pay dividends?

ME does not pay a dividend.


What is the Price/Earnings (PE) ratio of 23ANDME HOLDING CO -CLASS A (ME)?

23ANDME HOLDING CO -CLASS A (ME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.2).


What is the Short Interest ratio of 23ANDME HOLDING CO -CLASS A (ME) stock?

The outstanding short interest for 23ANDME HOLDING CO -CLASS A (ME) is 6.9% of its float. Check the ownership tab for more information on the ME short interest.


ME Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ME Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ME. The financial health of ME is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ME Financial Highlights

Over the last trailing twelve months ME reported a non-GAAP Earnings per Share(EPS) of -13.2. The EPS decreased by -29.41% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -192.93%
ROE -603.67%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1347.49%
Sales Q2Q%-11.86%
EPS 1Y (TTM)-29.41%
Revenue 1Y (TTM)-28.48%

ME Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 42% to ME. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of -329.17% and a revenue growth 22.44% for ME


Ownership
Inst Owners24.69%
Ins Owners9.89%
Short Float %6.9%
Short Ratio5.27
Analysts
Analysts42
Price Target2.12 (-12.4%)
EPS Next Y-329.17%
Revenue Next Year22.44%